×
About 4,392 results

ALLMedicine™ Mastocytosis Center

Research & Reviews  1,873 results

Assessing vaccination reactions in pediatric patients with maculopapular cutaneous mast...
https://doi.org/10.1111/pde.14492
Pediatric Dermatology REFERENCES; Johansen ML, Lawley LP

Jan 4th, 2021 - Immunization compliance in the United States is declining, in part due to misinformation and fear surrounding adverse vaccination reactions. Recently, there have been data published in the allergy and immunology literature to show that there may b...

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681091
Theranostics Kluin-Nelemans HC, Jawhar M et. al.

Jan 4th, 2021 - In systemic mastocytosis (SM), the clinical features and survival vary greatly. Patient-related factors determining the outcome in SM are largely unknown. Methods: We examined the impact of sex on the clinical features, progression-free survival (...

Addressing the Challenges of Eosinophilia and Mastocytosis.
https://doi.org/10.1093/ajcp/aqaa206
American Journal of Clinical Pathology; Rimsza L, Craig FE et. al.

Dec 28th, 2020 - Addressing the Challenges of Eosinophilia and Mastocytosis.|2020|Rimsza L,Craig FE,Reichard KK,Kelemen K,George TI,|

Rare presentation of adult-onset cutaneous mastocytoma of the breast.
https://www.ncbi.nlm.nih.gov/pubmed/33342184
Dermatology Online Journal; Kim J, Malakouti M et. al.

Dec 20th, 2020 - Mastocytosis is a rare condition in which mast cells accumulate throughout various organs of the body-the most common subtype being confined to the skin. We present an unusual case of cutaneous mastocytosis localized to the unilateral breast of a ...

A case report on concurrent occurrence of systemic mastocytosis and myeloid sarcoma pre...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738061
Medicine Wang X, Zhang L et. al.

Dec 17th, 2020 - Systemic mastocytosis is a rare disease due to mast cell accumulation in various extracutaneous sites. Systemic mastocytosis with an associated clonal hematologic non-MC lineage disease is the second most common subtype of systemic mastocytosis. T...

see more →

Guidelines  3 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JNCCN; Gotlib J, Gerds AT et. al.

Dec 13th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/12/1500.full
Gotlib, J.

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt.

Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of t...
https://doi.org/10.1111/all.12436
Allergy Valent P, Escribano L et. al.

May 19th, 2014 - Mastocytosis is an emerging differential diagnosis in patients with more or less specific mediator-related symptoms. In some of these patients, typical skin lesions are found and the diagnosis of mastocytosis can be established. In other cases, ho...

see more →

Drugs  267 results see all →

Clinicaltrials.gov  2,183 results

Ranitidine - ranitidine tablet, film coated-Quality Care Products, LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1d55e87-41f7-4556-95af-0854c1b1c1bd

Jan 10th, 2021 - Ranitidine tablets USP are indicated in: 1.Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more t...

Assessing vaccination reactions in pediatric patients with maculopapular cutaneous mast...
https://doi.org/10.1111/pde.14492
Pediatric Dermatology REFERENCES; Johansen ML, Lawley LP

Jan 4th, 2021 - Immunization compliance in the United States is declining, in part due to misinformation and fear surrounding adverse vaccination reactions. Recently, there have been data published in the allergy and immunology literature to show that there may b...

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681091
Theranostics Kluin-Nelemans HC, Jawhar M et. al.

Jan 4th, 2021 - In systemic mastocytosis (SM), the clinical features and survival vary greatly. Patient-related factors determining the outcome in SM are largely unknown. Methods: We examined the impact of sex on the clinical features, progression-free survival (...

Addressing the Challenges of Eosinophilia and Mastocytosis.
https://doi.org/10.1093/ajcp/aqaa206
American Journal of Clinical Pathology; Rimsza L, Craig FE et. al.

Dec 28th, 2020 - Addressing the Challenges of Eosinophilia and Mastocytosis.|2020|Rimsza L,Craig FE,Reichard KK,Kelemen K,George TI,|

Ranitidine - ranitidine solution-Amneal Pharmaceuticals LLC
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f0bb213-6342-4fea-a080-24def590d1ba

Dec 28th, 2020 - Ranitidine Oral Solution is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more th...

see more →

News  59 results

Gene-targeting therapy shown to reduce mastocytosis symptoms
https://www.mdedge.com/familymedicine/article/219888/asthma/gene-targeting-therapy-shown-reduce-mastocytosis-symptoms?channel=39313
CHEST Physician; Richard Mark Kirkner

Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.

Update on Rosacea Classification and Its Controversies
https://www.mdedge.com/dermatology/article/204310/rosacea/update-rosacea-classification-and-its-controversies/page/0/1?channel=291

Jul 9th, 2019 - However, the Expert Committee still did not define either the length of time of flushing or nontransient erythema. It also did not specify convex surfaces of the face with periocular sparing as the characteristic pattern or provide additional info.

Inhibitor can improve symptoms of systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/190755/cythemias/inhibitor-can-improve-symptoms-systemic-mastocytosis?channel=50517
Jen Smith

Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.

A Case of Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disease at VA Pittsburgh Healthcare System
https://www.mdedge.com/fedprac/avaho/article/174895/lymphoma-plasma-cell-disorders/case-systemic-mastocytosis-associated
Liman AD, Gandhi A et. al.

Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.

Avapritinib produces durable responses in SM
https://www.mdedge.com/hematology-oncology/article/184888/leukemia-myelodysplasia-transplantation/avapritinib-produces-durable
HT Staff

Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.

see more →

Patient Education  7 results see all →